C-Reactive Protein Testing Market Expansion Forecasted at 2.7% CAGR

The global C-reactive protein (CRP) testing market, valued at USD 1,834.23 million in 2023, is poised for steady growth, projected to reach USD 2,331.22 million by 2032, expanding at a compound annual growth rate (CAGR) of 2.7% from 2023 to 2032. This growth is driven by the rising prevalence of chronic inflammatory conditions, cardiovascular diseases, and an increasing reliance on diagnostic tools for disease risk assessment and treatment monitoring.

As healthcare systems prioritize early detection, point-of-care diagnostics, and personalized medicine, CRP testing remains a critical component in the management of numerous medical conditions, from infections to autoimmune diseases.

Market Overview

C-reactive protein is a biomarker of inflammation produced by the liver in response to inflammation in the body. Elevated CRP levels are indicative of a wide range of conditions, including bacterial infections, rheumatoid arthritis, cardiovascular diseases, and inflammatory bowel disease. CRP testing is widely used in clinical practice for early detection, disease monitoring, and evaluating treatment efficacy.

Key growth drivers for the CRP testing market include:

Increasing incidence of chronic diseases, particularly cardiovascular and autoimmune disorders.
Growing adoption of point-of-care testing (POCT) in primary care and emergency settings.
Rising awareness about preventive healthcare and inflammation screening.
Technological advancements in high-sensitivity CRP (hs-CRP) testing and automated immunoassay platforms.

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞:

https://www.polarismarketresearch.com/industry-analysis/c-reactive-protein-testing-market

Market Segmentation

The CRP testing market is segmented based on type of assay, detection range, application, end-user, and region.

By Type of Assay

Immunoturbidimetric Assay

Most widely used method in clinical laboratories.
Known for its rapid turnaround time and compatibility with automated analyzers.

ELISA (Enzyme-Linked Immunosorbent Assay)

Offers high sensitivity and specificity.
Common in research settings and some clinical diagnostics.

High-Sensitivity CRP (hs-CRP) Assays

Key for cardiovascular risk stratification.
Increasingly recommended for routine cardiac risk assessments.

Chemiluminescence Immunoassay (CLIA)

Provides enhanced accuracy and faster processing in high-throughput labs.

Others (e.g., Lateral Flow Assay)

Used in point-of-care and home testing environments.

By Detection Range

Conventional CRP (3–10 mg/L)

Used for detecting active inflammation and bacterial infections.

High-Sensitivity CRP (<3 mg/L)

Focused on predicting cardiovascular events and low-grade inflammation.

By Application

Cardiovascular Disease

Largest application segment due to hs-CRP’s role in predicting heart disease.

Infectious Disease

CRP helps differentiate between bacterial and viral infections.

Rheumatoid Arthritis and Autoimmune Conditions

Used for monitoring disease activity and therapy effectiveness.

Inflammatory Bowel Disease (IBD)
Cancer

Emerging application for assessing systemic inflammation in oncology patients.

By End-User

Hospitals and Clinics

Major market share; bulk of CRP testing is performed here.

Diagnostic Laboratories

Increasingly adopting automated, high-throughput platforms.

Point-of-Care Testing Centers

Key growth segment; portable devices improving access in rural and urgent care settings.

Academic and Research Institutes

Focused on understanding CRP’s broader implications in systemic diseases.

Regional Analysis

North America

2023 Market Share: ~40%
The United States dominates due to high rates of cardiovascular and chronic inflammatory diseases, advanced diagnostic infrastructure, and routine use of hs-CRP in primary care.
Favorable reimbursement policies and awareness campaigns drive growth.

Europe

High penetration of CRP testing in the UK, Germany, and France.
National health systems encourage early diagnosis and disease monitoring through blood biomarker testing.
Research initiatives into inflammation's role in chronic illness bolster demand.

Asia-Pacific

Fastest-growing regional market due to:

Large populations with rising non-communicable disease burdens.
Expanding public health programs in countries like China and India.
Growing demand for affordable point-of-care diagnostics in rural and underserved areas.

Latin America

Increasing uptake in countries like Brazil, Argentina, and Mexico.
Improving healthcare access and chronic disease burden fuel demand.

Middle East & Africa

Emerging market with significant potential.
Investments in healthcare infrastructure and diagnostics to support population health initiatives.

Key Companies

The global CRP testing market is characterized by the presence of both multinational diagnostics companies and regional players offering varied assay technologies.

1. Abbott Laboratories

Offers a range of hs-CRP and standard CRP assays compatible with its ARCHITECT platform.
Strong presence in point-of-care diagnostics.

2. Roche Diagnostics

Leader in high-throughput and automated testing platforms.
Provides CRP tests through the Cobas system.

3. Thermo Fisher Scientific

Supplies ELISA kits and reagents for CRP research and clinical use.

4. Siemens Healthineers

Offers CRP testing through immunoassay analyzers used in hospital laboratories.

5. Danaher Corporation (Beckman Coulter, Radiometer)

Provides automated hs-CRP solutions and point-of-care blood gas analyzers with CRP functionality.

6. Horiba

Known for compact CRP analyzers suitable for near-patient testing.

7. Euroimmun (PerkinElmer)

Offers research-grade and clinical CRP assay kits.

Trends and Opportunities

Point-of-Care Innovation: Miniaturized CRP testing devices are being developed for rapid testing in clinics, ambulances, and home-care settings.
Integration with Electronic Health Records (EHR): Test results are increasingly integrated with digital health platforms for better patient monitoring and risk stratification.
Preventive Healthcare Focus: Governments and private insurers are encouraging inflammation testing for chronic disease prevention and management.
CRP in Personalized Medicine: Research into CRP as a component in multi-biomarker panels for personalized treatment plans is expanding.

Challenges

Limited Awareness in Low-Income Regions: Many healthcare providers lack awareness of hs-CRP’s predictive value in cardiovascular disease.
Reimbursement Variability: CRP test coverage differs across countries, affecting access and affordability.
False Positives: CRP is a general marker of inflammation and not disease-specific, requiring careful clinical interpretation.

Conclusion

The global CRP testing market continues to expand, supported by its crucial role in identifying and monitoring inflammation in a wide array of diseases. With advances in assay technologies, rising demand for decentralized testing, and greater emphasis on early diagnosis, CRP testing is expected to become increasingly integral to modern clinical decision-making.

Industry stakeholders, from diagnostics manufacturers to healthcare providers, are poised to benefit from the rising demand for rapid, reliable, and accessible inflammatory biomarker testing in the coming decade.

𝐁𝐫𝐨𝐰𝐬𝐞 𝐌𝐨𝐫𝐞 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭𝐬:

Bipolar Disorder Treatment Market

Facial Injectable Market

Brain Tumor Diagnosis and Therapeutics Market

Flexible Paper Packaging Market

X-Ray Photoelectron Spectroscopy Market

Blood Plasma Market

Audiology Devices Market

Disinfection And Sterilization Equipment Market

Ebola Vaccines Market

Epilepsy Drugs Market

Blood Transfusion Diagnostics Market